| 周晓丹,冀国发,刘 亚,叶新丽,高学飞.替雷利珠联合白蛋白紫杉醇治疗晚期肺癌的疗效分析及对T细胞亚群的影响[J].,2022,(11):2128-2132 |
| 替雷利珠联合白蛋白紫杉醇治疗晚期肺癌的疗效分析及对T细胞亚群的影响 |
| Efficacy Analysis of Tislelizumab Combined with Albumin Paclitaxel in the Treatment of Advanced Lung Cancer and Its Influence on T Cell Subsets |
| 投稿时间：2022-01-12 修订日期：2022-01-31 |
| DOI：10.13241/j.cnki.pmb.2022.11.025 |
| 中文关键词: 替雷利珠 白蛋白紫杉醇 肺癌 T细胞亚群 |
| 英文关键词: Tislelizumab Albumin paclitaxel Lung cancer T cell subsets |
| 基金项目:陕西省自然科学基础研究计划项目（2017JQ8027） |
|
| 摘要点击次数: 832 |
| 全文下载次数: 416 |
| 中文摘要: |
| 摘要 目的：研究替雷利珠联合白蛋白紫杉醇治疗晚期肺癌的疗效分析，并探讨其对T细胞亚群的影响。方法：选择2018年7月到2021年10月在院接受治疗的晚期肺癌患者80例，根据治疗方式不同分为单一治疗组和联合组，每组40例。单一治疗组患者接受白蛋白紫杉醇治疗，联合组患者接受替雷利珠联合白蛋白。比较两组患者治疗后临床疗效、不良反应以及治疗前后血清IgA和IgG含量，以及外周血CD4+和CD8+T细胞亚群。结果：（1）联合组患者临床治疗有效率为87.5 %，显著高于单一治疗组67.5 %的临床治疗有效率（P<0.05）；（2）两组患者治疗后肝肾损伤、呕吐、乏力、白细胞减少、神经毒性以及手足综合征等不良反应发生率无显著差异（P>0.05）；（3）联合组患者治疗后血清IgA和IgG均显著高于单一治疗组患者（P<0.05）；（4）联合组治疗后CD4+和CD4+/CD8+T淋巴细胞比例均显著高于单一治疗组（P<0.05），而CD8+T淋巴细胞比例均显著低于单一治疗组（P<0.05）。结论：替雷利珠联合白蛋白紫杉醇治疗可以显著提高晚期肺癌患者临床治疗有效率，但不增加不良反应发生率，并可有效改善患者免疫功能。 |
| 英文摘要: |
| ABSTRACT Objective: To study the efficacy of tislelizumab combined with albumin paclitaxel in the treatment of advanced lung cancer, and to explore its effect on T cell subsets. Methods: 80 patients with advanced lung cancer who were treated in the hospital from July 2018 to October 2021 were selected and divided into monotherapy group and joint group according to different treatment methods, with 40 cases in each group. The monotherapy group received albumin paclitaxel treatment, and the joint group received tisleli beads combined with albumin. To compare the clinical efficacy, adverse reactions, serum IgA and IgG levels before and posttreatment, and peripheral blood CD4+ and CD8+T cell subsets between the two groups of patients. Results: (1) The clinical treatment effective rate of patients in the joint group was 87.5 %, which was higher than the clinical treatment effective rate of 67.5 % in the monotherapy group (P<0.05); (2) Liver and kidney damage, vomiting, fatigue, and leukopenia in the two groups of patients posttreatment There was no difference in the incidence of adverse reactions such as neurotoxicity and hand-foot syndrome(P>0.05); (3) Serum IgA and IgG of patients in the joint group posttreatment were higher than those in the monotherapy group(P<0.05); (4) Study posttreatment, the ratio of CD4+ and CD4+/CD8+T lymphocytes in the group was higher than that of the monotherapy group (P<0.05), while the ratio of CD8+T lymphocytes was lower than that of the monotherapy group (P<0.05). Conclusion: The treatment of tisleli beads combined with albumin paclitaxel can significantly improve the clinical treatment efficiency of patients with advanced lung cancer, but does not increase the incidence of adverse reactions, and can effectively improve the immune function of patients. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
